Citius Pharmaceuticals Inc. (NASDAQ:CTXR) and Tenax Therapeutics Inc. (NASDAQ:TENX) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Citius Pharmaceuticals Inc.||1||0.00||N/A||-0.81||0.00|
|Tenax Therapeutics Inc.||1||0.00||N/A||-7.65||0.00|
Table 1 showcases the gross revenue, earnings per share and valuation of Citius Pharmaceuticals Inc. and Tenax Therapeutics Inc.
Table 2 provides us the return on assets, return on equity and net margins of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Citius Pharmaceuticals Inc.||0.00%||-52.4%||-46.2%|
|Tenax Therapeutics Inc.||0.00%||-175.2%||-156.5%|
Risk and Volatility
Citius Pharmaceuticals Inc. is 53.00% less volatile than Standard & Poor’s 500 because the stock has a beta of 0.47. Tenax Therapeutics Inc.’s 40.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 1.4 beta.
The Current Ratio and a Quick Ratio of Citius Pharmaceuticals Inc. are 1 and 1. Competitively, Tenax Therapeutics Inc. has 11 and 11 for Current and Quick Ratio. Tenax Therapeutics Inc.’s better ability to pay short and long-term obligations than Citius Pharmaceuticals Inc.
Institutional & Insider Ownership
Citius Pharmaceuticals Inc. and Tenax Therapeutics Inc. has shares held by institutional investors as follows: 1.6% and 22.2%. Insiders held roughly 42.8% of Citius Pharmaceuticals Inc.’s shares. Insiders Comparatively, held 4.73% of Tenax Therapeutics Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Citius Pharmaceuticals Inc.||21.62%||35%||35%||36.36%||-49.06%||29.81%|
|Tenax Therapeutics Inc.||-2.96%||-6.43%||-21.56%||11.97%||-79.3%||8.26%|
For the past year Citius Pharmaceuticals Inc. was more bullish than Tenax Therapeutics Inc.
On 4 of the 6 factors Citius Pharmaceuticals Inc. beats Tenax Therapeutics Inc.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.